CTMX vs XNCR
CTMX: CytomX is developing conditionally activated cancer therapies using its PROBODY platform to enable selective tumor targeting with reduced systemic toxicity, starting with varsetatug masetecan for colorectal cancer. XNCR: Xencor is a clinical-stage biopharma using proprietary protein engineering to develop next-generation bispecific antibodies for cancer and autoimmune conditions.
Side-by-side fundamentals
| Metric | CTMX | XNCR | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $3.10 | $20.21 | |
| Market cap as of 2026-08-03 | $675M | $1.5B | |
| Net margin as of 2026-08-03 | -166.4% | -177.1% | CTMX higher |
| Operating margin as of 2026-08-03 | -181.9% | -222.4% | CTMX higher |
| ROE as of 2026-08-03 | -36.6% | -28.8% | XNCR higher |
| ROA as of 2026-08-03 | -28.0% | -20.5% | XNCR higher |
| Debt / equity as of 2026-08-03 | 0.00 | 0.21 | CTMX lower |
| Revenue growth (YoY) as of 2026-08-03 | -75.9% | -25.4% | XNCR higher |
| Revenue CAGR (3y) SEC XBRL | +12.8% | -8.6% | CTMX higher |
| Beta as of 2026-08-03 | 1.31 | 1.51 | |
| 1-year return as of 2026-07-31 close | +41.6% | +142.9% | XNCR higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.